AFFYXELL THERAPEUTICS
AffyXell was established in January 2020 by Avacta and Daewoong as a joint venture to develop novel mesenchymal stem cell (MSC) therapies.
AFFYXELL THERAPEUTICS
Industry:
Biotechnology Therapeutics
Founded:
2020-01-01
Address:
Seoul, Seoul-t'ukpyolsi, South Korea
Country:
South Korea
Total Employee:
1+
Status:
Active
Total Funding:
7.3 M USD
Similar Organizations
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
Remix Therapeutics
Remix Therapeutics is a biotechnology company.
Investors List
Avacta Group
Avacta Group investment in Corporate Round - AffyXell Therapeutics
Shinhan Venture Investment
Shinhan Venture Investment investment in Series A - AffyXell Therapeutics
Kolon Investment
Kolon Investment investment in Series A - AffyXell Therapeutics
Samsung Venture Investment
Samsung Venture Investment investment in Series A - AffyXell Therapeutics
Shinhan Investment
Shinhan Investment investment in Series A - AffyXell Therapeutics
Stonebridge Ventures
Stonebridge Ventures investment in Series A - AffyXell Therapeutics
Gyeongnam Venture Investment
Gyeongnam Venture Investment investment in Series A - AffyXell Therapeutics
Smilegate Investment
Smilegate Investment investment in Series A - AffyXell Therapeutics
More informations about "AffyXell Therapeutics"
아피셀테라퓨틱스
AffyXell Therapeutics Co., Ltd. CEO. Seongsoo Park Company Registration Number. 119-88-01693 [email protected] Address. (Headquarters) Gimhae Biomedical Industry Promotion Institute Techno Town Room 404, 80 …See details»
아피셀테라퓨틱스
박성수 사업자등록번호. 119-88-01693 [email protected] 주소.(본사) 경상남도 김해시 주촌면 골든루트로 80-59 김해의생명산업진흥원 테크노타운 404호 / (AFX플랫폼연구소) 경기도 용인시 수지구 광교중앙로 338 …See details»
AffyXell Therapeutics - Crunchbase Company Profile
AffyXell Therapeutics closed its last funding round on Apr 13, 2022 from a Corporate Round round. Who are AffyXell Therapeutics 's competitors? …See details»
AffyXell Therapeutics, Co., Ltd. - LinkedIn
AffyXell Therapeutics Co., Ltd. is a joint venture between Daewoong Pharmaceutical and Avacta Group, developing a novel cell & gene therapy to obstacle diseases that come from the imbalance of ...See details»
AffyXell Therapeutics 2025 Company Profile: Valuation, …
AffyXell Therapeutics General Information Description. Developer of next-generation of cell and gene therapies intended to treat inflammatory and …See details»
아피셀테라퓨틱스 - affyxell.com
AffyXell Therapeutics Co., Ltd. CEO. Seongsoo Park Company Registration Number. 119-88-01693 [email protected] Address. (Headquarters) Gimhae Biomedical Industry …See details»
AffyXell Therapeutics - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Apr 13, 2022: Corporate …See details»
AffyXell Therapeutics, Co., Ltd. - VentureRadar
AffyXell Therapeutics Co., Ltd. is developing a novel cell & gene therapy based on mesenchymal stem cell (MSC) to obstacle the diseases that come from imbalance of immune system …See details»
AffyXell Therapeutics Co., Ltd. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for AffyXell Therapeutics Co., Ltd. of Gimhae, Gyeongnam. Get the latest business insights from Dun & …See details»
AffyXell Therapeutics - Products, Competitors, Financials, …
AffyXell Therapeutics specializes in the development of novel cell and gene therapies within the biotechnology sector. The company's main offerings include therapies aimed at restoring …See details»
AffyXell Successfully Completes Funding Round | Avacta …
Jul 21, 2022 Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary …See details»
Technology - 아피셀테라퓨틱스
AffyXell Therapeutics Co., Ltd. CEO. Seongsoo Park Company Registration Number. 119-88-01693 [email protected] Address. (Headquarters) Gimhae Biomedical Industry …See details»
Research programme: stem cell therapies - AffyXell Therapeutics
Aug 28, 2024 Stem-cell therapies, incorporating Affimer proteins in mesenchymal stem cells (MSCs) are being developed by AffyXell Therapeutics (a joint venture of Avacta and Research …See details»
Avacta Achieves Second Milestone in AffyXell Joint Venture …
Jun 5, 2023 Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, is pleased to announce that a second …See details»
AffyXell partners with Biocytogen and the Korea Non-clinical …
Apr 8, 2022 Sengho Jeon, Chief Executive Officer of Daewoong Pharmaceutical and AffyXell Therapeutics, said: “Through this contract, the capabilities of the three companies can exert a …See details»
AffyXell successfully completes funding round - Cambridge Network
Jul 25, 2022 The funding will also allow AffyXell to develop the broader pipeline of cell therapies to address a wide range of immune diseases with high unmet needs, and to reinforce its …See details»
AffyXell $7.3 Million Series A Financing - FT.com
Feb 1, 2021 Avacta Group plc (AIM: AVCT), the developer of Affimer ® biotherapeutics and reagents, is pleased to announce that AffyXell Therapeutics ("AffyXell"), the joint venture with …See details»
아피셀테라퓨틱스
AffyXell provides a new class of affordable cellular therapeutics that help patients recover from intractable disease and regain their health. AffyXell Therapeutics Co., Ltd. CEO. Seongsoo …See details»
Affyxell Therapeutics to conduct more efficient preclinical trials ...
Apr 7, 2022 Affyxell Therapeutics will conduct proof-of-concept and toxicity testing of many of its drug candidates using animal and disease models developed through this collaboration. The …See details»
Life sciences joint venture closes multi-million pound investment …
Feb 1, 2021 Life sciences business Avacta Group says AffyXell Therapeutics – its joint venture with Daewoong Pharmaceutical – has closed a Series A venture capital investment of …See details»